Free tool
FAERS Monitor: Blujepa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218230 or its brand name (Blujepa, Gepotidacin Mesylate). Reports on generic versions are filed under their own applications.
Reports
33
Serious
2
6% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea8
- drug ineffective5
- off label use3
- abdominal pain2
- dizziness2
- dysarthria2
- nausea2
- abdominal pain upper1
- asthenia1
- back pain1
- drug intolerance1
- dysuria1
- faeces soft1
- feeling abnormal1
- hospitalisation1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 31 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,126 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| faeces soft | 1 | 87.6 | 12.7 | 21 |
| dysarthria | 2 | 33.9 | 8.8 | 35 |
| dysuria | 1 | 17.3 | 2.5 | 3 |
| diarrhoeaSignal | 8 | 7.9 | 4.3 | 43 |
| drug intolerance | 1 | 6.6 | 1.0 | 1 |
| abdominal pain | 2 | 5.5 | 1.4 | 4 |
| hospitalisation | 1 | 4.1 | 0.6 | 0 |
| abdominal pain upper | 1 | 3.1 | 0.4 | 0 |
| back pain | 1 | 2.7 | 0.4 | 0 |
| feeling abnormal | 1 | 2.7 | 0.4 | 0 |
| dizziness | 2 | 2.6 | 0.7 | 1 |
| drug ineffective | 5 | 2.4 | 1.1 | 3 |
| off label use | 3 | 2.2 | 0.7 | 1 |
| asthenia | 1 | 1.7 | 0.2 | 0 |
| nausea | 2 | 1.6 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.